Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > ZANAMIVIR HYDRATE CAS 139110-80-8

ZANAMIVIR HYDRATE CAS 139110-80-8

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 139110-80-8

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
139110-80-8
Appearance::
Colorless Crystalline Solid
Molecular Formula::
C12H20N4O7
Molecular Weight::
332.31000
EINECS NO::
691-117-1
MDL NO::
MFCD39110808
CAS NO::
139110-80-8
Appearance::
Colorless Crystalline Solid
Molecular Formula::
C12H20N4O7
Molecular Weight::
332.31000
EINECS NO::
691-117-1
MDL NO::
MFCD39110808
ZANAMIVIR HYDRATE CAS 139110-80-8

Product Description:

Product Name: ZANAMIVIR HYDRATE CAS NO: 139110-80-8

 

 

Synonyms:

5-acetamido-4-guanidino-2,3,4,5-tetradeoxy-D-glycero-D-galacto-non-2-enopyranosonic acid;

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid 4-Guanidino-Neu5Ac2en;

Zanamivir Hydrate;

 

 

Chemical & Physical Properties:

Appearance: Colorless crystalline solid

Assay :≥99.0%

Density: 1.75 g/cm33

Melting Point: 256℃ (dec.)

Index of Refraction: 1.679

 

 

Safety Information:

Symbol: GHS07

Signal Word: Warning

Hazard Statements: H302-H315-H319-H335

Precautionary Statements: P261-P305 + P351 + P338

Hazard Code: Xn

Risk Phrases: 22-36/37/38

Safety Phrases: 26

 

 

Zanamivir INN is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.